Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App




Reliable Screening Tool Found for Lung Cancer Subtype

By LabMedica International staff writers
Posted on 31 Dec 2012
Immunohistochemistry (IHC) has been found to be reliable screening tool for identification of the anaplastic lymphoma kinase (ALK) positive rearrangement in non-small-cell lung cancer (NSCLC). More...


The identification of an effective therapy for ALK-positive NSCLC places great emphasis on rapid, accurate, and cost-effective way to find patients with this subtype of lung cancer, although the complex fluorescence in situ hybridization (FISH) is the current standard method to detect ALK rearrangement.

The FISH technology is not readily available as a routine method of pathology practice in most laboratories because it is time consuming and requires advanced technical and professional expertise. In contrast, IHC is relatively inexpensive, faster, and is perfectly adapted for routine practice by academics and most community hospitals.

Scientists led by those at University of British Columbia (Vancouver, BC, Canada) screened 377 stage I or II NSCLC cases in a tissue microarray by FISH and IHC (Leica Microsystems; Wetzlar, Germany) or using the N-Histofine ALK detection kit (Nichirei Biosciences; Tokyo, Japan) and monoclonal antibodies. IHC was scored as 0, 1+, 2+, or 3+. Possible positive or positive cases were further analyzed by IHC and FISH on whole sections.

Tissue microarray results were available on 377 cases by IHC and 273 cases by FISH. Eleven cases were positive or possibly positive by either IHC or FISH, and three cases were positive or possibly positive by both methods. Three cases were ALK-positive by FISH on whole section validation. There was no correlation between semi-quantitative IHC score (1+, 2+, 3+) and ALK rearrangement by FISH. The rabbit monoclonal anti-human CD246 clone D5F3 (Cell Signaling, Danvers, MA, USA) and the Novocastra mouse anti-ALK monoclonal 5A4 (Newcastle upon Tyne, UK) showed the greatest combination of 100% sensitivity with a specificity of 87.5% for 5A4 and 75% for D5F3 and neither produced false-negative results.

The authors concluded that IHC is a reliable screening tool for identification of ALK rearrangement in NSCLC and is antibody dependent. The D5F3 from Cell Signaling and 5A4 from Novocastra can be used with FISH for identification of IHC-positive cases to reduce screening costs. In addition, all cases exhibiting ALK rearrangement demonstrated adenocarcinoma histology and the results report a sensitivity of 100% and high specificity with the IHC with no false-negative results. The study was published in the January 2013 issue of the Journal of Thoracic Oncology.

Related Links:

University of British Columbia
Leica Microsystems
Cell Signaling



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
New
Alzheimer's Disease Biomarker Assay
Elecsys Phospho-Tau (217P) Plasma
Gold Member
Electrolyte Analyzer
CBS-4000 (CBS-400)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Measuring six variants from one sample may improve research efficiency and support clinical trials of amyloid biology in Alzheimer’s disease and related conditions (Image Credit: Adobe Stock)

Plasma Assay Measures Six Amyloid Beta Peptides for Alzheimer’s Treatment Research

Alzheimer’s disease research and related neurological studies often require tools that can characterize brain amyloid pathology and amyloid beta biology. Blood-based biomarker assays may help researchers... Read more

Molecular Diagnostics

view channel
Image: A new study links broad genomic sequencing before first-line therapy to longer survival, supporting its role in treatment decisions (Image Credit: Shutterstock)

Study Supports Broad Genomic Profiling Before First-Line Lung Cancer Treatment

Biomarker testing plays a critical role in advanced non-small cell lung cancer by identifying patients who may benefit from targeted therapies. However, testing only one or two genes can miss actionable... Read more

Immunology

view channel
Image: The findings underscore the importance of aligning allergy testing with clinical history and diagnostic guidelines to reduce inappropriate testing and its consequences (Image Credit: iStock)

Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice

Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more

Industry

view channel
Image Credit: iStock

C2N Makes PrecivityAD2 Alzheimer’s Blood Test Available to Clinicians

Diagnosing Alzheimer’s disease can be challenging, particularly in patients with mild cognitive impairment or early dementia. Assessing brain amyloid pathology can guide clinical decisions, but diagnostic... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.